In pursuit of new anti-angiogenic therapies for cancer treatment

Jun Cai, Song Han, Ruan Qing, Daiqing Liao, Brian Law, Michael E. Boulton

Research output: Contribution to journalArticle

16 Scopus citations


Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of antiangiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.

Original languageEnglish (US)
Pages (from-to)803-814
Number of pages12
JournalFrontiers in Bioscience
Issue number3
StatePublished - Jan 1 2011


  • Anti-angiogenic Therapy
  • Endothelial cells
  • Review
  • Tumor angiogenesis
  • Vasculature

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'In pursuit of new anti-angiogenic therapies for cancer treatment'. Together they form a unique fingerprint.

  • Cite this

    Cai, J., Han, S., Qing, R., Liao, D., Law, B., & Boulton, M. E. (2011). In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in Bioscience, 16(3), 803-814.